ETRA
NASDAQ HealthcareElectra Therapeutics, Inc. - Common stock
Biotechnology
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.
๐ Market Data
| Price | $13.25 |
|---|---|
| Volume | 5,120,378 |
| Market Cap | 809.58M |
| 52-Week High | $15.50 |
| 52-Week Low | $13.25 |
๐ฏ Investment Strategy Scores
ETRA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (69/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ETRA in your text
Paste any article, transcript, or post โ the tool will extract ETRA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.